Nasopharyngeal carcinoma(NPC)is a malignant tumor that mainly occurs in East and Southeast Asia.Although patients benefit from the main NPC treatments(e.g.,radiotherapy and concurrent chemotherapy),persistent and recu...Nasopharyngeal carcinoma(NPC)is a malignant tumor that mainly occurs in East and Southeast Asia.Although patients benefit from the main NPC treatments(e.g.,radiotherapy and concurrent chemotherapy),persistent and recurrent diseases still occur in some NPC patients.Therefore,investigating the pathogenesis of NPC is of great clinical significance.In the present study,replication factor c subunit 4(RFC4)is a key potential target involved in NPC progression via bioinformatics analysis.Furthermore,the expression and mechanism of RFC4 in NPC were investigated in vitro and in vivo.Our results revealed that RFC4 was more elevated in NPC tumor tissues than in normal tissues.RFC4 knockdown induced G2/M cell cycle arrest and inhibited NPC cell proliferation in vitro and in vivo.Interestingly,HOXA10 was confirmed as a downstream target of RFC4,and the overexpression of HOXA10 attenuated the silencing of RFC4-induced cell proliferation,colony formation inhibition,and cell cycle arrest.For the first time,this study reveals that RFC4 is required for NPC cell proliferation and may play a pivotal role in NPC tumorigenesis.展开更多
基金the National Key Research and Development Program of China(Nos.2022YFA1103900 and 2020YFC2002705)the National Natural Science Foundation of China(Nos.82260715,82073092,and 82273076)+4 种基金the Guangxi Natural Science Foundation(Nos.2017GXNSFBA198240,2018GXNSFAA050055,and 2021GXNSFAA075038)Youth Fund Project of Natural Science Research Project of Guangxi University of Traditional Chinese Medicine(No.2016QN007)Guangxi Collaborative Innovation Center for Research on Functional Ingredients of Agricultural Residues(No.CICAR2016-P6)the CAMS Innovation Fund for Medical Sciences(CIFMS2021-RC310-003,2021-I2M-1-014).
文摘Nasopharyngeal carcinoma(NPC)is a malignant tumor that mainly occurs in East and Southeast Asia.Although patients benefit from the main NPC treatments(e.g.,radiotherapy and concurrent chemotherapy),persistent and recurrent diseases still occur in some NPC patients.Therefore,investigating the pathogenesis of NPC is of great clinical significance.In the present study,replication factor c subunit 4(RFC4)is a key potential target involved in NPC progression via bioinformatics analysis.Furthermore,the expression and mechanism of RFC4 in NPC were investigated in vitro and in vivo.Our results revealed that RFC4 was more elevated in NPC tumor tissues than in normal tissues.RFC4 knockdown induced G2/M cell cycle arrest and inhibited NPC cell proliferation in vitro and in vivo.Interestingly,HOXA10 was confirmed as a downstream target of RFC4,and the overexpression of HOXA10 attenuated the silencing of RFC4-induced cell proliferation,colony formation inhibition,and cell cycle arrest.For the first time,this study reveals that RFC4 is required for NPC cell proliferation and may play a pivotal role in NPC tumorigenesis.